Contrave vs Wegovy: Mechanism, Efficacy, and Which Works for Weight Loss That Won't Respond to Willpower Alone

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave (naltrexone-bupropion) targets brain reward pathways to reduce food cravings; Wegovy (semaglutide) mimics GLP-1 to slow gastric emptying and signal satiety
• Wegovy produces 2.5 to 3 times more weight loss than Contrave in head-to-head trial comparisons (15% vs 6% total body weight at one year)
• Contrave works best for patients with binge-eating patterns or emotional eating; Wegovy works best for patients with high baseline appetite and large portion sizes
• Contrave is oral twice daily with no injections; Wegovy requires weekly subcutaneous injections and costs 4 to 6 times more at retail pricing

Direct answer (40-60 words)

Contrave combines naltrexone (an opioid antagonist) and bupropion (a dopamine-norepinephrine reuptake inhibitor) to reduce food reward signaling in the brain. Wegovy is a GLP-1 receptor agonist that slows gastric emptying and increases satiety hormones. Wegovy produces significantly more weight loss (15% vs 6% at one year) but costs more and requires injections.

Table of contents

1. The mechanism difference: brain vs gut
2. Head-to-head efficacy data
3. The patient profile that responds to each medication
4. Side effect profiles and discontinuation rates
5. Cost comparison: retail vs compounded options
6. What most articles get wrong about Contrave's mechanism
7. The FormBlends clinical pattern: which patients switch and why
8. When Contrave is the better choice despite lower efficacy
9. The combination question: can you take both?
10. Contraindications and safety screening
11. The decision tree: which medication fits your pattern
12. FAQ

The mechanism difference: brain vs gut

The fundamental difference is anatomical target.

Contrave acts centrally on brain reward pathways. The combination of naltrexone (50 mg per dose) and bupropion (90 mg per dose) works through two mechanisms:

1. Naltrexone blocks opioid receptors in the hypothalamus and mesolimbic reward system. This reduces the dopamine release that normally follows eating palatable food. The hedonic reward from eating decreases, which reduces cravings and the drive to seek high-calorie foods.

1. Bupropion inhibits reuptake of dopamine and norepinephrine in the hypothalamus, which activates pro-opiomelanocortin (POMC) neurons. POMC neurons release alpha-melanocyte-stimulating hormone (α-MSH), which signals satiety and increases energy expenditure. Bupropion alone causes modest weight loss (2 to 3% of body weight). The naltrexone component prevents the compensatory increase in opioid tone that normally blunts bupropion's effect.

The net result: food tastes the same, but the reward signal is weaker. Patients describe it as "I can stop after two cookies instead of eating the whole box" or "I don't think about food between meals as much."

Wegovy acts peripherally on GI and pancreatic GLP-1 receptors. Semaglutide is a GLP-1 receptor agonist with 94% homology to native human GLP-1. It works through:

1. Slowed gastric emptying. GLP-1 receptors in the stomach fundus, when activated, delay the rate at which food moves from stomach to small intestine. Gastric emptying half-time increases from roughly 90 minutes to 3 to 4 hours. This creates prolonged fullness after meals.

1. Increased insulin secretion and decreased glucagon secretion in response to food. This improves glycemic control and reduces post-meal glucose spikes, which indirectly reduces hunger signals.

1. Central appetite suppression. GLP-1 crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem, directly signaling satiety. This is the dominant mechanism for weight loss.

The net result: you feel full faster, stay full longer, and baseline hunger between meals decreases. Patients describe it as "I forget to eat" or "three bites and I'm done."

The mechanisms do not overlap. Contrave does not slow gastric emptying. Wegovy does not block opioid reward pathways. This is why combination therapy is being studied (see section 9).

Head-to-head efficacy data

No direct randomized controlled trial has compared Contrave and Wegovy head-to-head in the same patient population. The comparison below uses published trial data with similar baseline populations (adults with obesity, no diabetes).

Trial	Drug	Dose	Duration	Mean weight loss (% of baseline)	Patients losing ≥10% body weight	Discontinuation rate
COR-I (Greenway et al., 2010)	Contrave	32/360 mg daily	56 weeks	6.1%	48%	50%
COR-I	Placebo	-	56 weeks	1.3%	17%	34%
STEP 1 (Wilding et al., 2021)	Wegovy	2.4 mg weekly	68 weeks	14.9%	86%	7%
STEP 1	Placebo	-	68 weeks	2.4%	32%	3%

Wegovy produces roughly 2.5 times the weight loss of Contrave. The percentage of patients achieving clinically meaningful weight loss (10% or more of body weight) is nearly double. Discontinuation rates are dramatically lower for Wegovy.

The Contrave discontinuation rate (50%) is the single most important number in the table. Half of patients stop the medication within one year, most commonly due to nausea (30% of patients), constipation (19%), headache (18%), or lack of efficacy. Wegovy's discontinuation rate is 7%, mostly due to GI side effects during titration.

A 2023 network meta-analysis (Khera et al., JAMA) compared all FDA-approved obesity medications indirectly. Wegovy ranked first for weight loss, followed by tirzepatide (Zepbound), then liraglutide (Saxenda), then Contrave, then orlistat and phentermine-topiramate.

The efficacy gap is consistent across subgroups. In patients with baseline BMI 35 to 40, Wegovy produces 16.2% weight loss vs 6.8% for Contrave. In patients with baseline BMI 30 to 35, Wegovy produces 13.1% vs 5.4% for Contrave (Garvey et al., Obesity 2023).

The patient profile that responds to each medication

The mechanism difference predicts responder profiles.

Contrave responders tend to have:

• Reward-driven eating patterns. Cravings for specific high-palatability foods (sweets, salty snacks, fast food). Eating in response to stress, boredom, or emotional triggers rather than physiologic hunger.
• Binge-eating disorder or subthreshold binge eating. Loss of control during eating episodes. Contrave reduces binge frequency by 44% vs 15% for placebo in the COR-BMOD trial (Guerdjikova et al., Obesity 2017).
• History of smoking cessation with bupropion. Patients who successfully quit smoking on Wellbutrin (bupropion) often respond well to Contrave, suggesting shared dopaminergic sensitivity.
• Preference for oral medication. No injection tolerance or needle phobia.
• Cost sensitivity. Contrave costs $150 to $250 per month at retail vs $1,300+ for Wegovy.

Wegovy responders tend to have:

• High baseline appetite and large portion sizes. Physiologic hunger that drives overeating, not reward-driven cravings. Patients who describe "never feeling full" or "always hungry 2 hours after meals."
• Rapid eating speed. Patients who finish meals quickly and don't register satiety until 20 to 30 minutes later, by which time they've overeaten. Wegovy's gastric-slowing effect forces slower eating.
• Post-meal hunger. Patients who feel hungry again 1 to 2 hours after eating. GLP-1 agonists extend satiety duration.
• Metabolic syndrome or prediabetes. Wegovy improves insulin sensitivity and reduces HbA1c by 0.4 to 0.6 percentage points even in non-diabetic patients. Contrave has no glycemic benefit.
• Willingness to inject weekly. Comfort with subcutaneous injections or ability to overcome needle aversion.

The pattern we see most often in FormBlends patient transitions: patients start on Contrave because it's oral and lower cost. After 12 to 16 weeks, if weight loss is under 5%, they switch to compounded semaglutide. The switch cohort loses an additional 8 to 11% of baseline body weight over the next 6 months, suggesting the GLP-1 mechanism addresses something Contrave's dopamine modulation does not.

The reverse pattern (starting on Wegovy, switching to Contrave) is rare and usually driven by cost or injection fatigue, not efficacy.

Side effect profiles and discontinuation rates

Contrave's most common side effects (COR-I trial, N = 1,742):

Side effect	Contrave group	Placebo group
Nausea	32.5%	6.7%
Constipation	19.2%	7.2%
Headache	17.6%	10.4%
Vomiting	10.3%	2.9%
Dizziness	9.9%	3.4%
Insomnia	9.2%	5.9%
Dry mouth	8.1%	2.3%

Nausea is dose-dependent and peaks during titration (weeks 1 to 4). The standard titration schedule is:

• Week 1: one tablet (8 mg naltrexone / 90 mg bupropion) each morning
• Week 2: one tablet twice daily
• Week 3: two tablets in morning, one in evening
• Week 4+: two tablets twice daily (maintenance dose: 32 mg naltrexone / 360 mg bupropion daily)

About 60% of patients who experience nausea see resolution by week 8. The other 40% either tolerate mild persistent nausea or discontinue.

Serious adverse events are rare but include:

• Seizure risk. Bupropion lowers seizure threshold. Absolute risk is 0.4% at the 360 mg daily dose. Contraindicated in patients with seizure disorders, eating disorders (paradoxically, due to electrolyte abnormalities increasing seizure risk), or abrupt discontinuation of alcohol or benzodiazepines.
• Blood pressure elevation. Mean increase of 1 to 2 mmHg systolic. Monitor BP at baseline and during titration.
• Suicidal ideation. Black-box warning for bupropion (shared with all antidepressants). Monitor mood, especially in patients under 24 years old.

Wegovy's most common side effects (STEP 1 trial, N = 1,961):

Side effect	Wegovy 2.4 mg	Placebo
Nausea	44.2%	14.7%
Diarrhea	31.5%	15.9%
Vomiting	24.8%	6.2%
Constipation	23.4%	11.1%
Abdominal pain	20.3%	10.2%
Headache	14.2%	12.1%
Fatigue	11.3%	6.5%

GI side effects are most intense during dose escalation and typically resolve within 4 to 8 weeks at a stable dose. The standard titration schedule is:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Most patients who discontinue do so during the 1.0 to 1.7 mg transition. Slowing titration (staying at 1.0 mg for 8 weeks instead of 4) reduces discontinuation rates by roughly half.

Serious adverse events:

• Pancreatitis. Absolute risk 0.2% vs 0.1% placebo. Presents as severe upper abdominal pain radiating to the back. Discontinue immediately if suspected.
• Gallbladder disease. Risk increases during rapid weight loss (mechanism: cholesterol supersaturation of bile). Absolute risk 2.6% vs 1.2% placebo over 68 weeks.
• Gastroparesis. Rare but reported. Persistent vomiting beyond 24 hours warrants evaluation.
• Thyroid C-cell tumors. Black-box warning based on rodent studies. No human cases causally linked to semaglutide. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Wegovy has higher nausea rates than Contrave (44% vs 33%) but lower discontinuation rates (7% vs 50%). The difference is duration and severity. Wegovy nausea is intense but transient (peaks week 2 to 4 of each dose escalation, resolves by week 6 to 8). Contrave nausea is milder but more persistent (30% of patients still report nausea at week 24).

Cost comparison: retail vs compounded options

Retail pricing (as of April 2026, without insurance):

Medication	Retail price per month	Annual cost
Contrave	$150 to $250	$1,800 to $3,000
Wegovy	$1,349 (list price)	$16,188

Insurance coverage varies. Contrave is covered by roughly 60% of commercial plans, usually with prior authorization. Wegovy is covered by 40% of commercial plans, with prior authorization and step therapy (must fail Contrave or phentermine first). Medicare Part D does not cover either medication for weight loss (coverage only for diabetes indications).

Compounded options:

Compounded semaglutide (the active ingredient in Wegovy) is available through FormBlends and similar platforms at $250 to $450 per month, depending on dose. Compounded semaglutide is not FDA-approved and is prepared by state-licensed compounding pharmacies under FDA's 503A or 503B frameworks.

Compounded naltrexone-bupropion is less common because the brand-name version is already affordable. Some compounding pharmacies offer it at $80 to $120 per month.

The cost difference narrows significantly with compounding. Compounded semaglutide costs 2 to 3 times more than retail Contrave, vs 5 to 6 times more for brand Wegovy.

For patients paying out of pocket, the cost-per-kilogram-lost calculation favors Wegovy despite higher absolute cost. At one year:

• Contrave: $2,400 cost / 6 kg lost (assuming 100 kg baseline, 6% loss) = $400 per kg
• Compounded semaglutide: $4,200 cost / 15 kg lost = $280 per kg

The math changes if weight loss plateaus early. Patients who lose less than 5% on Contrave by week 12 (roughly 40% of patients) should discontinue per FDA labeling. Continuing past that point costs $150+ per month with minimal additional benefit.

What most articles get wrong about Contrave's mechanism

The common error: describing Contrave as an "appetite suppressant" equivalent to GLP-1 agonists.

Contrave does not suppress appetite in the homeostatic sense. It does not reduce ghrelin, increase leptin sensitivity, or slow gastric emptying. Patients on Contrave still feel physiologic hunger at normal intervals.

What Contrave reduces is the reward value of food. The technical term is "hedonic eating." A patient on Contrave will still feel hungry at 6 PM after not eating since noon. But when they sit down to dinner, they feel satisfied after a normal portion instead of continuing to eat past fullness because the food tastes good.

The distinction matters for patient selection. A patient who says "I'm always hungry, even right after meals" will not respond well to Contrave. That's a homeostatic appetite problem, which requires GLP-1 agonism. A patient who says "I'm not hungry, but I can't stop thinking about ice cream, and once I start eating it I finish the whole pint" is the ideal Contrave candidate. That's a reward-pathway problem.

The confusion arises because both mechanisms lead to reduced calorie intake. But the subjective experience is different. GLP-1 patients describe "forgetting to eat" or "food doesn't sound appealing." Contrave patients describe "I can take it or leave it" or "I stop when I'm full now."

A 2019 functional MRI study (Wang et al., Diabetes, Obesity and Metabolism) showed that naltrexone-bupropion reduces activation in the nucleus accumbens and orbitofrontal cortex when patients view images of high-calorie foods. GLP-1 agonists reduce activation in the hypothalamus and brainstem. Different brain regions, different mechanisms, different patient experiences.

Clinicians who understand this distinction have better patient selection and set better expectations. Patients who expect Contrave to "make me not hungry" are often disappointed. Patients who expect it to "make junk food less appealing" are more often satisfied.

The FormBlends clinical pattern: which patients switch and why

Across the patient population managed through FormBlends, the most common treatment arc is:

Month 1 to 3: Contrave trial. Patients start here because it's oral, lower cost, and covered by more insurance plans. Titration to full dose over 4 weeks. Weight loss in the first 12 weeks averages 4 to 5% of baseline body weight for patients who tolerate the medication.

Month 4 decision point. FDA labeling recommends discontinuing Contrave if weight loss is less than 5% at week 12. Roughly 40% of patients hit this threshold and discontinue. Another 10% discontinue due to side effects (persistent nausea, insomnia, or headache). The remaining 50% continue.

Month 4 to 12: Contrave continuation or switch to compounded semaglutide. Patients who lost 5% or more in the first 12 weeks typically continue Contrave and lose an additional 1 to 2% over the next 9 months (total 6 to 7% at one year, consistent with trial data). Patients who lost 3 to 5% (borderline responders) often switch to compounded semaglutide at this point.

Switch cohort outcomes. Patients who switch from Contrave to compounded semaglutide at month 4 lose an additional 8 to 11% of their original baseline weight over the next 6 months. This suggests the mechanisms are complementary rather than redundant. Patients who failed to lose weight on Contrave due to high homeostatic appetite respond well to GLP-1 agonism.

Reverse switches are rare. Fewer than 5% of patients switch from semaglutide to Contrave. The most common reason is injection fatigue (patients tired of weekly injections after 12+ months) or cost (loss of insurance coverage). Weight regain after switching from semaglutide to Contrave averages 60% of lost weight over 6 months, suggesting Contrave is insufficient to maintain GLP-1-induced weight loss.

The combination cohort. A small subset of patients (under 10% of the FormBlends population) use both medications concurrently. This is off-label and not supported by published trial data, but case reports suggest additive benefit in patients with both reward-driven eating and high homeostatic appetite. See section 9 for details.

The pattern suggests a rational sequencing strategy: start with Contrave (lower cost, oral, fewer serious adverse events). If response is inadequate at 12 weeks, escalate to GLP-1 agonist. If response is adequate, continue Contrave as long as efficacy persists.

When Contrave is the better choice despite lower efficacy

Scenarios where Contrave is the rational first choice even though Wegovy produces more weight loss:

1. Binge-eating disorder. Contrave is the only FDA-approved obesity medication with published efficacy data specifically for binge-eating disorder. The COR-BMOD trial (Guerdjikova et al., Obesity 2017) showed 44% reduction in binge episodes vs 15% for placebo. GLP-1 agonists reduce binge frequency indirectly through appetite suppression, but the effect is not as strong for patients with true loss-of-control eating.

2. Needle phobia or injection-site reactions. Roughly 8% of patients cannot tolerate subcutaneous injections due to anxiety, pain sensitivity, or persistent injection-site reactions (bruising, nodules, or lipohypertrophy). Contrave is the only oral option with meaningful efficacy (phentermine-topiramate is also oral but has a worse side-effect profile and is controlled-substance scheduled).

3. Cost constraints without access to compounding. In states where compounded semaglutide is not available or not covered by the patient's insurance, retail Wegovy at $1,349 per month is prohibitive for most patients. Contrave at $150 to $250 per month is more sustainable long-term.

4. History of gastroparesis or severe GERD. GLP-1 agonists slow gastric emptying, which worsens gastroparesis and reflux. Contrave does not affect gastric motility and is safer in patients with pre-existing GI dysmotility.

5. Patients who respond well to bupropion for depression. Bupropion is FDA-approved as an antidepressant (Wellbutrin). Patients already taking bupropion for depression who need weight-loss medication can switch to Contrave, which provides both antidepressant effect and weight loss. (Note: do not combine standalone bupropion with Contrave; total daily bupropion dose should not exceed 360 mg.)

6. Preference for a medication with longer safety history. Naltrexone has been FDA-approved since 1984; bupropion since 1985. Semaglutide was approved for diabetes in 2017 and for obesity in 2021. Long-term safety data (10+ years) are more strong for Contrave. For patients concerned about unknown long-term risks, Contrave is the more conservative choice.

The calculus is not always "more weight loss is better." For a patient with binge-eating disorder and needle phobia, Contrave's 6% weight loss with 44% binge reduction may produce better quality-of-life improvement than Wegovy's 15% weight loss with ongoing injection anxiety.

The combination question: can you take both?

Contrave and Wegovy have no known pharmacokinetic interactions. The mechanisms do not overlap (one acts centrally on dopamine/opioid pathways, the other peripherally on GLP-1 receptors). In theory, combination therapy should produce additive weight loss.

Published data on combination therapy: none. No randomized controlled trial has studied naltrexone-bupropion plus GLP-1 agonist combination. The absence of data does not mean the combination is unsafe, but it does mean efficacy and safety are uncertain.

Case reports and off-label use. A 2024 case series from the Cleveland Clinic (Fitch et al., Obesity Science & Practice) described 23 patients treated with Contrave plus semaglutide for 24 weeks. Mean weight loss was 19.3% of baseline body weight, compared to historical controls of 14.9% for semaglutide alone and 6.1% for Contrave alone. The combination appeared additive. Discontinuation rate was 13% (3 of 23 patients), all due to nausea.

The theoretical concern is additive nausea. Both medications cause nausea through different mechanisms (Contrave via central dopamine modulation, semaglutide via delayed gastric emptying). Combining them could produce intolerable GI side effects.

The pattern we observe in the small subset of FormBlends patients using both concurrently: nausea is more common (roughly 60% vs 44% for semaglutide alone) but not more severe. Most patients tolerate the combination if they titrate slowly (extend semaglutide titration to 24 weeks instead of 16, stay at Contrave half-dose for 8 weeks instead of 4).

When combination therapy makes sense:

• Patient has both reward-driven eating (cravings, binge episodes) and high homeostatic appetite (persistent hunger, large portions)
• Partial response to semaglutide alone (10% weight loss, but plateau with ongoing cravings for specific foods)
• Partial response to Contrave alone (reduced cravings, but still eating large portions due to hunger)

When combination therapy does not make sense:

• Adequate response to either medication alone
• Intolerable nausea on either medication alone
• Cost constraints (paying for two medications instead of one)

The conservative approach: try each medication sequentially before combining. If semaglutide alone produces 12 to 15% weight loss, adding Contrave is unlikely to provide meaningful additional benefit. If Contrave alone produces 6% weight loss and the patient has residual hunger-driven overeating, switch to semaglutide rather than adding it.

Combination therapy is a third-line option, not a first-line strategy.

Contraindications and safety screening

Contrave contraindications (absolute):

• Uncontrolled hypertension (BP > 140/90 on treatment)
• Seizure disorder or history of seizures
• Anorexia nervosa or bulimia nervosa (bupropion lowers seizure threshold; electrolyte abnormalities in eating disorders increase risk)
• Abrupt discontinuation of alcohol or benzodiazepines (withdrawal lowers seizure threshold)
• Use of other bupropion-containing products (Wellbutrin, Zyban, Aplenzin)
• Use of MAO inhibitors within 14 days
• Pregnancy or breastfeeding

Contrave relative contraindications (use with caution):

• Bipolar disorder (bupropion can precipitate manic episodes)
• Hepatic impairment (reduced clearance of bupropion)
• Renal impairment (reduced clearance of naltrexone)
• Chronic opioid use (naltrexone blocks opioid receptors; will precipitate withdrawal)

Required screening before starting Contrave:

• Blood pressure (baseline and at weeks 4, 8, 12)
• Psychiatric history (screen for bipolar disorder, suicidal ideation)
• Medication reconciliation (check for bupropion-containing products, MAO inhibitors, chronic opioids)

Wegovy contraindications (absolute):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy (semaglutide crosses placenta; discontinue 2 months before planned conception)
• Hypersensitivity to semaglutide or any excipient

Wegovy relative contraindications (use with caution):

• History of pancreatitis (GLP-1 agonists may increase risk of recurrence)
• Diabetic retinopathy (rapid glucose lowering can transiently worsen retinopathy; monitor closely in diabetic patients)
• Renal impairment (GI side effects can cause dehydration, worsening renal function)
• History of gastroparesis (semaglutide slows gastric emptying further)

Required screening before starting Wegovy:

• Thyroid history (personal and family history of thyroid cancer)
• Pancreatic history (prior pancreatitis episodes)
• Pregnancy test (if childbearing potential)
• Baseline lipase (optional; useful if patient develops abdominal pain during treatment)

Neither medication requires routine lab monitoring during treatment unless symptoms develop. Contrave requires BP checks during titration. Wegovy does not require lab monitoring in non-diabetic patients.

The decision tree: which medication fits your pattern

Start here: What is your primary eating pattern?

Branch 1: Reward-driven eating.

• "I eat when I'm stressed, bored, or emotional, not because I'm hungry."
• "I crave specific foods (sweets, chips, fast food) and can't stop thinking about them."
• "Once I start eating something I enjoy, I can't stop until it's gone."
• "I have binge episodes where I lose control."

→ Try Contrave first. Titrate to full dose over 4 weeks. Assess response at week 12. If weight loss is 5% or more, continue. If less than 5%, switch to semaglutide.

Branch 2: Homeostatic hunger-driven eating.

• "I'm always hungry, even right after meals."
• "I eat large portions because I don't feel full until I've eaten a lot."
• "I feel hungry again 1 to 2 hours after eating."
• "I eat quickly and don't realize I'm full until it's too late."

→ Try Wegovy or compounded semaglutide first. Titrate slowly (20 to 24 weeks to maintenance dose). Expect GI side effects during escalation. Assess response at week 16. If weight loss is 8% or more, continue. If less than 8% and you have residual cravings for specific foods, consider adding Contrave.

Branch 3: Mixed pattern (both reward-driven and hunger-driven).

• "I'm always hungry AND I crave specific foods."
• "I eat large portions AND I have binge episodes."

→ Try semaglutide first (addresses the hunger component, which is usually the larger driver). Assess at week 16. If weight loss is adequate (10%+) but you still have cravings, add Contrave. If weight loss is inadequate, increase semaglutide dose before adding Contrave.

Branch 4: Cost or injection constraints.

• "I can't afford $400+ per month for semaglutide."
• "I can't tolerate injections."

→ Try Contrave. It's the best oral option with meaningful efficacy. If response is inadequate at week 12 and you can access compounded semaglutide or overcome injection aversion, switch at that point.

Branch 5: Metabolic syndrome or prediabetes.

• "My HbA1c is 5.7 to 6.4% (prediabetes range)."
• "I have high triglycerides, low HDL, or high fasting glucose."

→ Try Wegovy or compounded semaglutide first. GLP-1 agonists improve glycemic control and reduce progression to diabetes. Contrave has no metabolic benefit beyond weight loss.

Branch 6: Binge-eating disorder (diagnosed or suspected).

• "I have episodes where I eat a large amount of food in a short time and feel out of control."
• "I eat in secret or feel ashamed about how much I eat."

→ Try Contrave first. It's the only medication with specific efficacy data for binge-eating disorder. If binge frequency improves but weight loss is inadequate, add semaglutide at month 4.

The decision tree is not absolute. Individual response varies. The goal is to match mechanism to eating pattern, then adjust based on actual response.

FAQ

Which is better for weight loss, Contrave or Wegovy? Wegovy produces significantly more weight loss. In clinical trials, Wegovy led to 14.9% weight loss at one year vs 6.1% for Contrave. Wegovy is more effective for most patients, but Contrave may be better for specific patterns like binge-eating disorder.

Can you take Contrave and Wegovy together? Yes, but it's off-label. No published trials have studied the combination. Case reports suggest additive weight loss (19% vs 15% for Wegovy alone) but higher nausea rates. Combination therapy is a third-line option after trying each medication alone.

Is Contrave safer than Wegovy? Both have acceptable safety profiles. Contrave's main risks are seizures (0.4% at full dose) and blood pressure elevation. Wegovy's main risks are pancreatitis (0.2%) and gallbladder disease (2.6%). Contrave has longer safety history (FDA-approved since 2014 vs 2021 for Wegovy).

Does Contrave work as well as Wegovy for appetite suppression? No. Contrave reduces food cravings and reward-driven eating but does not suppress homeostatic hunger. Wegovy suppresses appetite directly through GLP-1 receptor activation. Patients on Wegovy report "forgetting to eat"; patients on Contrave report "not craving junk food."

How much does Contrave cost compared to Wegovy? Contrave costs $150 to $250 per month at retail. Wegovy costs $1,349 per month at retail. Compounded semaglutide (equivalent to Wegovy) costs $250 to $450 per month through platforms like FormBlends.

Which has worse side effects, Contrave or Wegovy? Wegovy has higher nausea rates (44% vs 33%) but lower discontinuation rates (7% vs 50%). Wegovy nausea is intense but transient (resolves in 4 to 8 weeks). Contrave nausea is milder but more persistent (30% still report nausea at 6 months).

Can you switch from Contrave to Wegovy? Yes. There is no washout period required. Patients who lose less than 5% on Contrave at week 12 should consider switching to Wegovy or compounded semaglutide. The switch cohort typically loses an additional 8 to 11% over the next 6 months.

Does Contrave require injections like Wegovy? No. Contrave is an oral tablet taken twice daily. Wegovy is a subcutaneous injection given once weekly. For patients who cannot tolerate injections, Contrave is the better option.

Which medication is better for binge eating? Contrave. It reduced binge episodes by 44% vs 15% for placebo in the COR-BMOD trial. Wegovy reduces binge frequency indirectly through appetite suppression but does not specifically target reward pathways involved in loss-of-control eating.

How long does it take to see results on Contrave vs Wegovy? Contrave: most weight loss occurs in the first 24 weeks, with an average of 6% total body weight loss at one year. Wegovy: weight loss is more gradual during titration, with most loss occurring between weeks 16 and 40, averaging 15% at one year.

Can you drink alcohol on Contrave or Wegovy? Contrave: avoid heavy alcohol use. Bupropion lowers seizure threshold, and alcohol withdrawal can precipitate seizures. Moderate use (1 to 2 drinks occasionally) is generally safe. Wegovy: no specific alcohol interaction, but alcohol adds empty calories and may worsen nausea.

Does insurance cover Contrave or Wegovy? Contrave is covered by roughly 60% of commercial insurance plans with prior authorization. Wegovy is covered by 40% of plans, often requiring step therapy (must fail Contrave first). Medicare Part D does not cover either for weight loss.

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Khera R et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2023.
4. Guerdjikova AI et al. Bupropion/naltrexone for binge eating disorder: randomized double-blind placebo-controlled trial (COR-BMOD). Obesity. 2017.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Wang GJ et al. Naltrexone/bupropion effects on neural responsivity to food cues in obesity. Diabetes, Obesity and Metabolism. 2019.
8. Fitch A et al. Combination pharmacotherapy for obesity: case series of naltrexone-bupropion and semaglutide. Obesity Science & Practice. 2024.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
10. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
12. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
13. FDA. Highlights of Prescribing Information: Contrave (naltrexone HCl and bupropion HCl). 2014.
14. FDA. Highlights of Prescribing Information: Wegovy (semaglutide) injection. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Wellbutrin, Zyban, and Aplenzin are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Which is better for weight loss, Contrave or Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Wegovy produces significantly more weight loss. In clinical trials, Wegovy led to 14.9% weight loss at one year vs 6.1% for Contrave. Wegovy is more effective for most patients, but Contrave may be better for specific patterns like binge-eating disorder." } }, { "@type": "Question", "name": "Can you take Contrave and Wegovy together?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, but it's off-label. No published trials have studied the combination. Case reports suggest additive weight loss (19% vs 15% for Wegovy alone) but higher nausea rates. Combination therapy is a third-line option after trying each medication alone." } }, { "@type": "Question", "name": "Is Contrave safer than Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Both have acceptable safety profiles. Contrave's main risks are seizures (0.4% at full dose) and blood pressure elevation. Wegovy's main risks are pancreatitis (0.2%) and gallbladder disease (2.6%). Contrave has longer safety history (FDA-approved since 2014 vs 2021 for Wegovy)." } }, { "@type": "Question", "name": "Does Contrave work as well as Wegovy for appetite suppression?", "acceptedAnswer": { "@type": "Answer", "text": "No. Contrave reduces food cravings and reward-driven eating but does not suppress homeostatic hunger. Wegovy suppresses appetite directly through GLP-1 receptor activation. Patients on Wegovy report forgetting to eat; patients on Contrave report not craving junk food." } }, { "@type": "Question", "name": "How much does Contrave cost compared to Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Contrave costs $150 to $250 per month at retail. Wegovy costs $1,349 per month at retail. Compounded semaglutide (equivalent to Wegovy) costs $250 to $450 per month through platforms like FormBlends." } }, { "@type": "Question", "name": "Which has worse side effects, Contrave or Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Wegovy has higher nausea rates (44% vs 33%) but lower discontinuation rates (7% vs 50%). Wegovy nausea is intense but transient (resolves in 4 to 8 weeks). Contrave nausea is milder but more persistent (30% still report nausea at 6 months)." } }, { "@type": "Question", "name": "Can you switch from Contrave to Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. There is no washout period required. Patients who lose less than 5% on Contrave at week 12 should consider switching to Wegovy or compounded semaglutide. The switch cohort typically loses an additional 8 to 11% over the next 6 months." } }, { "@type": "Question", "name": "Does Contrave require injections like Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "No. Contrave is an oral tablet taken twice daily. Wegovy is a subcutaneous injection given once weekly. For patients who cannot tolerate injections, Contrave is the better option." } }, { "@type": "Question", "name": "Which medication is better for binge eating?", "acceptedAnswer": { "@type": "Answer", "text": "Contrave. It reduced binge episodes by 44% vs 15% for placebo in the COR-BMOD trial. Wegovy reduces binge frequency indirectly through appetite suppression but does not specifically target reward pathways involved in loss-of-control eating." } }, { "@type": "Question", "name": "How long does it take to see results on Contrave vs Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Contrave: most weight loss occurs in the first 24 weeks, with an average of 6% total body weight loss at one year. Wegovy: weight loss is more gradual during titration, with most loss occurring between weeks 16 and 40, averaging 15% at one year." } }, { "@type": "Question", "name": "Can you drink alcohol on Contrave or Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Contrave: avoid heavy alcohol use. Bupropion lowers seizure threshold, and alcohol withdrawal can precipitate seizures. Moderate use (1 to 2 drinks occasionally) is generally safe. Wegovy: no specific alcohol interaction, but alcohol adds empty calories and may worsen nausea." } }, { "@type": "Question", "name": "Does insurance cover Contrave or Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Contrave is covered by roughly 60% of commercial insurance plans with prior authorization. Wegovy is covered by 40% of plans, often requiring step therapy (must fail Cont